RxDoctor Payments Data

Laurie Roba, MD

Ophthalmology · Pittsburgh, PANPI 1780679035

Payments from drug & device makers

$3,506in general payments, 2019–2025

Across 84 payments — averaging $41.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$811
  • Bausch & Lomb Americas Inc.$384
  • Alcon$324
  • AstraZeneca$208
  • AbbVie$198
  • Amgen$150
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,48799%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,506 in reported general payments places this provider in the 70th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$129,678
Medicare patients
589
Services billed
1,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine81$68,363
Cyclosporine146$63,020
XiidraLifitegrast44$29,608
Latanoprost1,498$14,544
MieboPerfluorohexyloctane/Pf18$13,568
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol28$8,127
Prednisolone Acetate143$6,655
IlevroNepafenac11$4,343
LumiganBimatoprost18$4,313
Timolol Maleate192$2,829
TafluprostTafluprost/Pf14$2,664
Dorzolamide Hcl104$2,188
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat87$2,167
MoxifloxacinMoxifloxacin Hcl113$1,473
Brimonidine Tartrate112$1,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$198$72,67699 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$384$43,17662 claims
NovartisIlevro$137$4,34311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →